Role of NRF2 Pathway in Neurodegenerative Diseases
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section “Health Outcomes of Antioxidants and Oxidative Stress“.
Deadline for manuscript submissions: 20 June 2024
Special Issue Editor
Dr. Isabel Lastres-Becker E-Mail | Website
Guest Editor
1. Instituto de Investigaciones Biomédicas “Sols-Moreale” UAM-CSIC, c/Arturo Duperier 4, 28029 Madrid, Spain
2. Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid, 28040 Madrid, Spain
3. Institute Teófilo Hernando for Drug Discovery, Universidad Autónoma de Madrid, 28029 Madrid, Spain
4. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain
Interests: neurodegenerative diseases; NRF2; oxidative stress; neuroinflammation; RNA-binding proteins; mitochondria
Special Issue Information
Dear Colleagues,
Although the trigger of the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. With age, a multitude of changes occur at the molecular level, such as an increase in oxidative stress and a decrease in the antioxidant capacity of an organism, with the decrease in the levels of the transcription factor NRF2 being one of the main causes of this imbalance. This creates a favorable environment for the development of neurodegenerative diseases. Although each of these diseases has its own characteristics, they all share altered proteostasis, oxidative stress and neuroinflammation. In recent years, it has been described that the transcription factor NRF2 is involved in the modulation of all these processes, becoming a pleiotropic factor. Therefore, understanding the involvement of NRF2 in the different mechanisms associated with neurodegeneration may be of vital importance in establishing new therapeutic targets.
As Guest Editor, I invite you to contribute to this Special Issue, whose focus will be the role of NRF2 in neurodegenerative disorders.
We also invite researchers in the field and the participants of the COST Action CA20121, Bench to Bedside Transition for Pharmacological regulation of NRF2 in non-communicable diseases (BenBedPhar), to submit their latest research findings to this Special Issue. We look forward to reading your contributions.
Dr. Isabel Lastres-Becker
Guest Editor
You can find all the information about in the button below
